Tepezza
生产厂家：美国Horizon Therapeutics(HZNP) 地平线治疗
功能主治：治疗甲状腺眼病的新型药物，改善患者眼球突出
用法用量：用法用量 Tepezza的推荐剂量是初始剂量为10mg/kg的静脉输注，然后每三周静脉输注20mg/kg，再输注7次。
查看详情
Tepezza works by targeting a specific protein called insulin-like growth factor 1 receptor (IGF-1R). This protein plays a crucial role in the development of TED, acting as a switch that turns on the abnormal immune responses leading to eye inflammation and tissue expansion. By blocking the activity of IGF-1R, Tepezza helps to reduce inflammation, prevent further tissue expansion, and ultimately improve the appearance and function of the eyes.
Clinical trials of Tepezza have shown remarkable results. One study involving 88 patients with severe TED found that 83% of those who received Tepezza experienced a significant reduction in the degree of eye protrusion compared to only 10% of those who received a placebo. Additionally, Tepezza-treated patients reported improvements in eye discomfort, visual function, and overall quality of life.The long-term effects of Tepezza have also been promising. Follow-up studies conducted over a period of several years have shown that the positive changes observed during the initial treatment with Tepezza persist, with the majority of patients maintaining their improved eye appearance and function. This indicates that Tepezza not only provides short-term relief but also offers a lasting solution for individuals with TED.
Apart from its efficacy, Tepezza has proven to be a safe treatment option. The most common side effects reported during clinical trials were muscle cramps and nausea, which were generally mild and temporary. Furthermore, Tepezza has not shown any significant interaction with other commonly used medications, making it suitable for patients with coexisting medical conditions.
The introduction of Tepezza has revolutionized the management of TED. Previously, treatment options were often limited to managing symptoms through the use of artificial tears, medications to reduce inflammation, and sometimes even surgery. However, these approaches did not address the root cause of the disease and could only provide temporary relief. With Tepezza, patients finally have a targeted therapy that directly addresses the underlying immune dysfunction, leading to significant and long-lasting improvements.
The impact of Tepezza extends beyond physical changes. Patients with TED often suffer from a loss of confidence and a negative impact on their quality of life due to the visible eye changes. The improvement in eye appearance and function resulting from Tepezza treatment can restore self-esteem and bring back a sense of normalcy for these individuals.
In conclusion, Tepezza (Teprotumumab-trbw) has emerged as a groundbreaking treatment for Thyroid Eye Disease. By specifically targeting the underlying cause of the condition, Tepezza has demonstrated significant improvements in eye appearance and function. With its long-lasting effects and favorable safety profile, Tepezza offers hope for individuals suffering from this challenging eye disease. This breakthrough medication has transformed the landscape of TED management, providing a new level of care and improving the quality of life for countless patients worldwide.
